Pentadecanoic acid (C15:0) is a 15-carbon saturated fatty acid found mainly in full-fat dairy products and the fat of ruminant animals. Until recently it was dismissed as a dietary curiosity, but a growing body of research — much of it from Epitracker researchers — has proposed that C15:0 may act as a partial agonist at peroxisome proliferator-activated receptors alpha and delta (PPAR-α and PPAR-δ), two nuclear receptors that sit at the center of fatty acid oxidation, glucose homeostasis, and mitochondrial biogenesis.
This article walks through what PPAR-α and PPAR-δ do, what the current published evidence says about C15:0’s interaction with these receptors, and where the science remains genuinely uncertain. The FDA has not evaluated C15:0 supplements for any disease, and the hypothesis that C15:0 is an ‘essential’ fatty acid — while scientifically interesting — has not been formally adopted by regulatory bodies or mainstream nutrition science. Everything here is informational, not medical advice.
Key Takeaways
- C15:0 is proposed to act as a partial agonist at PPAR-α and PPAR-δ, nuclear receptors that regulate fatty acid oxidation and metabolic gene expression [3].
- Animal studies show C15:0 upregulates liver PPAR-α, but the same research noted mild glucose intolerance effects at studied doses [2].
- A related odd-chain fatty acid, C19:0, has been shown to influence glucose homeostasis, suggesting this class of fatty acids may have metabolic relevance beyond simple energy provision [4].
- The hypothesis that C15:0 is an essential fatty acid is scientifically interesting but has not been formally adopted by regulatory bodies; most human evidence to date is limited in scale and duration.
- No serious adverse events have been reported at studied doses (100–300 mg/day), but long-term human safety and efficacy data are still needed.
What PPAR-Alpha and PPAR-Delta Do in the Body
Peroxisome proliferator-activated receptors are ligand-activated transcription factors — proteins that, when bound by the right molecule, travel to the cell nucleus and switch genes on or off. There are three subtypes: PPAR-α, PPAR-δ (also called PPAR-β/δ), and PPAR-γ. Each governs a partly distinct set of metabolic processes.
PPAR-α is expressed most highly in the liver, heart, and skeletal muscle. Its core job is to upregulate genes involved in fatty acid uptake and beta-oxidation — the process by which cells burn fat for fuel. Activating PPAR-α increases the transcription of enzymes like carnitine palmitoyltransferase I (CPT-1), which shuttles long-chain fatty acids into mitochondria, and enzymes of the ketogenic pathway. PPAR-δ is more ubiquitous and is particularly active in skeletal muscle and the gut, where it promotes fat burning, improves mitochondrial function, and is thought to support insulin sensitivity.
Because both receptors influence how cells handle fatty acids and glucose, they have attracted substantial pharmaceutical interest. Fibrate drugs used to lower triglycerides work partly through PPAR-α activation. The question researchers have begun asking is whether naturally occurring dietary fatty acids — including odd-chain saturated fatty acids like C15:0 — can engage the same receptors in a gentler, partial way.
How C15:0 Is Proposed to Activate PPAR-Alpha and PPAR-Delta
A 2025 review in the World Journal of Biological Chemistry summarized the proposed molecular and cellular mechanisms of pentadecanoic acid and described C15:0 as a partial agonist at both PPAR-α and PPAR-δ [3]. Unlike full agonists — which maximally activate the receptor regardless of context — partial agonists produce a submaximal response. This is sometimes considered advantageous because strong, continuous PPAR-α activation (as seen with high-dose fibrate therapy) can carry side effects; a partial agonist may offer metabolic signaling at a lower intensity.
The proposed binding mechanism involves C15:0 fitting into the ligand-binding domain of PPAR-α and PPAR-δ, triggering a conformational change that recruits co-activator proteins and initiates target gene transcription [3]. Because C15:0 is a 15-carbon odd-chain fatty acid, it is structurally distinct from the even-chain saturated fats (like palmitic acid, C16:0) that predominate in most Western diets, which may explain why it engages these receptors differently. Research using animal models found that C15:0 supplementation upregulated liver PPAR-α alongside MAPK signaling pathways [2], providing in vivo evidence consistent with the receptor activation hypothesis.
It is important to note that most mechanistic data comes from cell culture experiments and rodent models. Human pharmacokinetic and receptor-binding studies for C15:0 are limited, and the direct demonstration that dietary C15:0 reaches target tissues at concentrations sufficient for meaningful PPAR activation in humans has not yet been fully established.
Proposed Effects on Fat Oxidation and Energy Metabolism
If C15:0 genuinely activates PPAR-α in liver and muscle, the downstream expectation would be increased expression of fat-oxidation genes, potentially raising the rate at which cells burn long-chain fatty acids. The 2025 molecular review outlines this as one of C15:0’s primary proposed metabolic actions, situating it alongside effects on mitochondrial function, membrane integrity, and cellular aging pathways [3].
PPAR-δ activation in skeletal muscle is associated with a shift toward oxidative fiber types and enhanced mitochondrial density, effects that have been demonstrated with pharmaceutical PPAR-δ agonists in animal studies. Whether dietary C15:0 levels can drive this shift in human muscle tissue is an open question. The analogy to pharmaceutical agonists is instructive but should not be overextended: a drug designed to maximally activate a receptor at therapeutic plasma concentrations is a very different tool from a dietary fatty acid consumed in the context of a mixed meal.
C15:0, Glucose Regulation, and Hepatic Lipid Metabolism
PPAR-α activation in the liver promotes fatty acid oxidation and ketogenesis while suppressing de novo lipogenesis, effects that in theory could improve hepatic lipid profiles and insulin signaling. Animal research found that C15:0 administration upregulated liver PPAR-α and MAPK signaling and promoted offspring growth, though the same study noted that C15:0 also induced mild maternal glucose intolerance at the doses studied [2]. This nuance — that PPAR-α activation is not uniformly beneficial in all physiological contexts — is worth holding onto.
Research on a structurally related odd-chain fatty acid, nonadecanoic acid (C19:0), found that it could regulate glucose homeostasis through distinct cellular mechanisms [4]. While C15:0 and C19:0 are different molecules, this finding suggests that odd-chain saturated fatty acids as a class may interact with metabolic pathways governing blood glucose, supporting the broader hypothesis that C15:0 is not metabolically inert.
How hepatic lipid metabolism connects to dietary fatty acid composition was also explored in a Circulation Research review noting that full-fat dairy consumption — the primary dietary source of C15:0 — has been associated in epidemiological work with cardiovascular and metabolic outcomes not predicted by earlier saturated-fat models [1]. Whether C15:0 specifically drives those associations, or whether it is a marker for other components of full-fat dairy, cannot be determined from observational data alone.
Dietary Sources, Supplement Doses, and the 'Essential Fatty Acid' Hypothesis
C15:0 is found almost exclusively in full-fat dairy (butter, whole milk, aged cheese) and the fat of ruminant animals. Because most Western dietary guidelines have historically recommended reduced-fat dairy, average C15:0 intake in many populations is low — roughly 100–200 mg per day in high-dairy consumers and considerably less in those following low-fat patterns.
Epitracker researchers have proposed that C15:0 meets criteria for an essential fatty acid because the body cannot synthesize it efficiently and because deficiency appears associated with metabolic and cellular markers of poor health in their datasets [3]. This is a scientifically provocative hypothesis, but ‘essential’ has a specific regulatory and biochemical meaning — it has not been formally adopted by the FDA, WHO, or major nutrition bodies. Studied supplement doses range from 100 to 300 mg per day; no serious adverse events have been reported in published research at these doses, though long-term human safety data remain limited.
The fatty acid is commercially available as a purified supplement (sold under brand names like Fatty15). Individuals interested in raising dietary C15:0 can also do so by incorporating full-fat dairy, keeping in mind that full-fat dairy also contains saturated fatty acids with different metabolic profiles, and that total dietary context matters.
What the Evidence Actually Shows — and Where the Gaps Are
The published mechanistic picture for C15:0 is internally consistent and biologically plausible: a dietary odd-chain fatty acid that integrates into cell membranes, partially activates PPAR-α and PPAR-δ, and through those receptors modulates fat oxidation and cellular stress pathways [3]. Animal data support PPAR-α upregulation in the liver [2], and epidemiological associations between dairy-derived odd-chain fatty acids and metabolic health have been noted [1].
What is missing is a robust set of randomized controlled trials in humans measuring hard metabolic endpoints — HbA1c, triglycerides, liver fat, body composition — over meaningful time periods. The maternal glucose intolerance finding in one animal study [2] is a signal that dose and context matter and that PPAR-α activation is not categorically beneficial. Much of the mechanistic work cited by proponents relies on in vitro assays and rodent models, which do not always translate directly to human physiology. Independent replication of Epitracker-generated findings by other research groups is still sparse.
🛒 Where to Buy Pentadecanoic Acid (C15:0)
- Epitracker Fatty15 C15:0 Fatty Acid SupplementLab-tested / studied
capsules, 100 mg C15:0 per capsule; 1 capsule/day starter, 2 capsules/day maintenance — Category creator; the only C15:0 supplement backed by the original Epitracker research team (Venn-Watson et al.); uses a patented, sustainably-sourced pure C15:0 ingredient; most expensive per-capsule but reference product for all comparisons - Double Wood Supplements Pentadecanoic Acid C15:0
capsules, 200 mg C15:0 per serving (2 capsules) — One of the first genericized C15:0 supplements; significantly lower price than Fatty15; no independent clinical trials on this specific product; good option for budget-conscious buyers who want to trial the fatty acid - Sports Research Pentadecanoic Acid C15:0
softgels, 100 mg C15:0 per softgel — Established supplement brand with strong Amazon presence; third-party tested; softgel form may aid fat-soluble absorption; competitively priced mid-tier option - BulkSupplements Pentadecanoic Acid Powder (C15:0)
powder, 100–300 mg per measured serving — Most economical option for higher-dose protocols or stackers; requires a milligram-accurate scale; no excipients or additives; not recommended for beginners unfamiliar with powder dosing
As an Amazon Associate we earn from qualifying purchases. Shilajit quality varies widely — always choose a product with a published third-party heavy-metal test (COA) before buying.
A Note on the Evidence
The evidence for C15:0 as a PPAR agonist with meaningful metabolic effects in humans is promising but early, resting primarily on cell culture, animal models, and epidemiological associations rather than large-scale human trials; anyone with diabetes, metabolic syndrome, or who is pregnant should discuss C15:0 supplementation with a qualified healthcare provider before starting. This article is informational only and does not constitute medical advice; the FDA has not evaluated C15:0 supplements for the treatment or prevention of any disease.
Frequently Asked Questions
What does 'partial PPAR agonist' mean compared to a full agonist?
A partial agonist binds the same receptor as a full agonist but produces a submaximal activation response even at saturating concentrations. In the context of PPAR-α, this may mean metabolic signaling without the intensity associated with pharmaceutical fibrate drugs. C15:0 has been characterized as a partial PPAR-α and PPAR-δ agonist in molecular research [3], though the clinical implications of this distinction in humans are not yet fully characterized.
Does C15:0 actually burn fat?
Via PPAR-α activation, C15:0 is proposed to upregulate genes involved in fatty acid beta-oxidation — the biochemical process cells use to oxidize fat for energy [3]. However, the leap from receptor activation in cell or animal models to measurable fat loss in humans requires well-designed clinical trials that are currently limited. Calling C15:0 a ‘fat burner’ would go beyond what the evidence supports at this stage.
Is C15:0 safe at supplement doses?
Published research using doses of 100–300 mg per day has not reported serious adverse events. However, one animal study noted mild maternal glucose intolerance at studied doses, highlighting that dose and physiological context matter [2]. Long-term human safety data are limited, and individuals with metabolic conditions or who are pregnant should consult a healthcare provider before supplementing.
How is C15:0 different from other saturated fats like palmitic acid (C16:0)?
C15:0 is an odd-chain (15-carbon) saturated fatty acid, while palmitic acid is an even-chain (16-carbon) fatty acid. The two are metabolized differently: odd-chain fatty acids can enter the Krebs cycle via propionyl-CoA, a route not available to even-chain fats. This structural difference may underlie C15:0’s proposed distinct receptor interactions [3], as well as epidemiological observations linking odd-chain dairy fatty acids to metabolic outcomes [1].
Are other odd-chain fatty acids metabolically active too?
Yes. Research on nonadecanoic acid (C19:0), another odd-chain fatty acid, found it could regulate glucose homeostasis through cellular mechanisms distinct from insulin signaling [4]. This suggests that C15:0’s metabolic properties may reflect a broader characteristic of odd-chain fatty acids as a class, though each molecule has its own specific activities and research base.
Why has C15:0 been associated with full-fat dairy health outcomes?
Epidemiological research has observed that full-fat dairy consumption is not associated with the adverse cardiovascular outcomes that earlier saturated-fat models predicted, and researchers have explored whether specific bioactive components — including odd-chain fatty acids like C15:0 — help explain this [1]. C15:0 is a reliable biomarker of full-fat dairy intake, so it is difficult to separate its specific contribution from other dairy components. Observational associations cannot establish causation.
References
- Mozaffarian D et al. Flavonoids, Dairy Foods, and Cardiovascular and Metabolic Health: A Review of Emerging Biologic Pathways. Circulation research (2018). PMID 29348256
- Wang J et al. Pentadecanoic acid (C15:0, PA) induces mild maternal glucose intolerance and promotes the growth of the offspring partly through up-regulating liver PPARα and MAPK signaling pathways. Food & function (2024). PMID 39434548
- Mercola J et al. Molecular and cellular mechanisms of pentadecanoic acid. World journal of biological chemistry (2025). PMID 41378251
- Hou Y et al. A Novel Function of Nonadecanoic Acid in Regulating Glucose Homeostasis. Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2026). PMID 41738141
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
